shire map
Select a

Shire Global

Better Health, Brighter Future


Bleeding ConditionsAt Shire, our mission is to be champions for people around the world who are struggling with rare diseases. When it comes to rare and immune-mediated conditions, we serve individuals with these diseases and the physicians who treat them by providing therapies and services that can be tailored to each person’s unique needs–even as these needs change across the patient journey.

While each disease is different, the expectations of the individuals who live with them are similar. Shire’s strength in immunology is built on deep expertise in delivering complex therapies for a variety of conditions. To deliver on our promise as a rare champion, Shire’s goal is to provide:

Personalized Solutions

Intelligent, adaptable treatments that help manage, and prevent serious conditions, supported by services that support these individuals in using the best therapy for them, and adjusting their approach as needs change. In hereditary angioedema (HAE), we help give patients the freedom to live their lives, aided by patient services and next-generation therapies that improve their treatment experience.

Meaningful Advances

Ongoing progress that delivers new treatments and explores new ways of receiving them to continually advance the standard of care from symptom management to preventative therapies, as we work toward the ultimate goal of a cure. We offer the broadest immunoglobulin (IG) portfolio, and aspire to provide an intelligent set of flexible options to meet each patient’s need for effective care that fits their lives and improves the overall patient treatment experience. We also offer a broad biotherapeutic portfolio of products including Alpha-1, Albumin, Protein C, and pdFVIII designed to meet the needs of patients in both the hospital and at-home setting.

Expertise in Complex Manufacturing

Manufacturing expertise to confidently manage the end-to-end challenges of developing complex therapies, including those created from human plasma, from securing donations through to delivering treatment.

We support patients with immune-mediated conditions including:

Alpha-1 Antitrypsin Deficiency (AAT or Alpha-1 deficiency)

Alpha-1 Antitrypsin Deficiency (AAT or Alpha-1 deficiency) is a hereditary condition that results in reduced levels of alpha-1 antitrypsin (AAT) protein in the blood and lungs. This protein, which is made mostly in the liver, helps protect lung tissue from chemicals released by white blood cells.1 People with low levels of AAT protein are at higher risk for developing lung diseases such as emphysema.

Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE) is a rare disease that causes unexpected edema (swelling) in various parts of the body including extremities, the gastrointestinal tract, and upper airways. Depending on the severity of the disease, some people may have many attacks each month, while others will go months without an attack.

Primary immunodeficiency (PI)

Primary immunodeficiency (PI) is a group of nearly 300 rare diseases wherein part of the immune system is missing or not functioning properly2,3. People with PI may be more susceptible to illness, take longer to recover and have recurring infections4, such as sinusitis, bronchitis, pneumonia, or gastrointestinal infections5. Physicians sometimes treat the infections while missing the underlying cause, leaving patients vulnerable to vital organ damage, physical disability, or even increased mortality risk6,7.


  1. Alpha-1 Foundation “What is Alpha-1”. Brochure. Available at: Accessed January 31, 2018.
  2. Blaese RM, Bonilla FA, Stiehm ER, Younger ME, eds. Patient & Family Handbook for Primary Immunodeficiency Diseases. 5th ed. Towson, MD: Immune Deficiency Foundation; 2013.
  3. Bousfiha A, Jeddane I, Al-Herz W, et al. The 2015 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2015; 35(8): 727-738.
  4. Immune Deficiency Foundation, “About Primary Immunodeficiencies: Accessed April 18, 2016.
  5. Immune Deficiency Foundation, “About Primary Immunodeficiencies: Infections.” Accessed April 18, 2016.
  6. Riedl M, Rumbak M. Clin Pulm Med. 2010;17(2):88-95
  7. Resnick ES, et al. Blood. 2012;119(7):1650-1657.

S38372 03/18


Cookie Use Notification

The site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies as set out in our cookie notice. Please read our privacy notice for more information on the cookies we use and how to delete or block the use of cookies. LEARN MORE